IDEAYA Biosciences’ Post

Combining this agent with sotorasib has demonstrated improvements vs sotorasib monotherapy by yielding deeper tumor regressions and reducing the occurrence of disease relapse based on preclinical proof-of-concept data. https://lnkd.in/gJYkBpcJ #NSCLC #cancer #oncology

https://lnkd.in/gdSY62qN Mitomycin C and its analog trigger cytotoxicity in MCF-7 and K562 cancer cells through the regulation of RAS and MAPK/ERK pathways Owen Zacarias a 1, Cristina C. Clement b 1, Shu-Yuan Cheng a c, Melissa Rosas a, Christina Gonzalez a, Marion Peter d, Peter Coopman d, Elise Champeil a e 1 Both O. Zacarias and C.C. Clement share first authorship of this manuscript. 

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates #stockmarket #stocks #investing #businessnews #trading #daytrading

Tubulis GmbH doses first patient in phase 1/2a trial investigating #ADC candidate TUB-040 in ovarian cancer and lung adenocarcinoma (NSCLC). TUB-040 is a NaPi2b-targeting Exatecan ADC based on Tubulis’ proprietary linker technology with better biophysical properties that demonstrated effective and durable responses in a range of preclinical models. ℹ Read more: https://lnkd.in/gEZhZcaM

First-line treatment with ivonescimab (AK112; SMT112) monotherapy led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) monotherapy in patients with locally advanced or metastatic, PD-L1–positive non–small cell lung cancer (NSCLC), meeting the primary end point of the phase 3 HARMONi-2 trial (NCT05499390)OncLive https://lnkd.in/gj-HGWQP

💥The following paper: "Investigational Drug Treatments for Triple-Negative Breast Cancer" is published in the Journal of Personalized Medicine MDPI at: https://lnkd.in/gUTce5aJ We invite you to read this paper at the above link. And also hope that you could consider JPM (https://lnkd.in/g3jxwN_H) when submitting your next paper. #personalizedmedicine #precisionmedicine #breastcancer

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting #stockmarket #stocks #investing #businessnews #trading #daytrading #clinicaltrial

ELCC24 Great discussion of Antibody drug conjugates toxicity from Dr. Jarushka Naidoo, noting that each component of the antibody drug conjugate will impact toxicity - Stephen Liu Paolo Tarantino Jarushka Naidoo International Association for the Study of Lung Cancer ESMO - European Society for Medical Oncology #Cancer #DanaFarber #CancerInstitute #ELCC24 #ClinicalOncology #OncoDaily #Oncology

To finish the workweek, an example of the #speedofscience in the world of #oncology (#cancer). #crispr #multiomics #drugdiscovery #drugdevelopment #newmedsmatter #hope #cancerpatients https://lnkd.in/eaPkNeHJ

The FDA has granted Eisbach Bio GmbH IND approval for its drug candidate EIS-12656 👏 the world's first small molecule #therapy targeting the molecular machine ALC1, which is key #DNA damage and repair in several solid tumor indications. The superior #safety profile of EIS-12656, its brain penetrance and the non-overlapping resistance mechanisms with PARP inhibitors promise to transform #cancer therapy and enable the full potential of synthetic lethal drugs in the #clinic 💊. This marks Eisbach’s first #IND with the FDA for a drug candidate that emerges from our allosteric discovery engine 🏄♂️. We look forward to many more innovative products to come and to the start of our combined Phase I/II study 👩⚕️. Learn more: https://lnkd.in/eTC65FeW